The previous page is sending you to http://abbvie.mediaroom.com/2014-09-25-AbbVies-HUMIRA-adalimumab-Receives-U-S-FDA-Approval-for-the-Treatment-of-Pediatric-Patients-with-Moderately-to-Severely-Active-Crohns-Disease.

 If you do not want to visit that page, you can return to the previous page.